A Case of Dystrophic Epidermolysis Bullosa Improved with Etanercept for Concomitant Psoriatic Arthritis

Epidermolysis bullosa is a group of inherited, chronic, non-inflammatory skin disorders, and dystrophic epidermolysis bullosa (DEB) is one of the most severe variants. The role of tumour necrosis factor alpha (TNFα) has not been reported in the pathogenesis of DEB. A DEB case is reported that appears to have responded well to the TNFα inhibitor etanercept given for the treatment of concomitant psoriatic arthritis. A progressive improvement in DEB was apparent over the first 3 months of treatment and persistent good control of DEB was noted over 3 years of therapy. A correlation between DEB improvement and etanercept has not been made, but the case may provide insight into the causal mechanisms of DEB.